RSS Feed - Life Sciences - Transactions - Kaye Scholer LLP
Current Feed: http://www.kayescholer.com/practice/rss.xml?p=life_sciences_transactions
Andres Liivak (08/14/14)
Andres Liivak is the Co-Chair of Kaye Scholer’s Life Sciences Industry Group and a Partner in the firm’s Corporate Department. Working together with the firm’s highly regarded, collaborative, multidisciplinary life sciences team, Andres helps life sciences healthcare industry clients develop comprehensive solutions and manage risk to achieve their business objectives. In his practice, Andres focuses on putting in place new deals as well as counseling with respect to and renegotiating existing transactions, including:
- Priority, high value deals – examples include in-licenses of blockbuster drugs; acquisitions of target companies and products, including with sales force; divestures of approved products together with supply chain transition; collaborative development and commercialization license arrangements; contentious renegotiation of major commercial contracts relating to key products; and settlement of major IP and contract litigation with business deals.
- Deals outside a client's comfort zone or recent experience – examples include co-promotion arrangements and companion diagnostic deals.
- Unusually complex, novel deals – some recent examples include multi-party, multi-product collaborations involving co-development, co-commercialization and exclusive supply arrangements.
Viktoriya Karshenboyem (08/04/14)
Viktoriya Karshenboyem is an Associate in the New York office of Kaye Scholer. She focuses her practice on corporate and finance transactions, including mergers and acquisitions, private equity investments, licensing and collaboration agreements, and securities offerings. She also advises U.S. and international companies, both private and public, on general corporate matters, including corporate governance and securities laws compliance. In addition, Viktoriya advises financial institutions and other borrowers and lenders in the areas of commercial lending and structured finance.